Updated:
Linus Health
Bates founded the Boston-based company alongside Pascual-Leone and two partners from Tamarisc Ventures, structuring the venture at the intersection of...
Linus Health
Bates founded the Boston-based company alongside Pascual-Leone and two partners from Tamarisc Ventures, structuring the venture at the intersection of clinical neurology and enterprise software. The group acquired Digital Cognition Technologies in 2020, gaining the digitized DCTclock™ — a sensor-laden assessment that captures sub-second drawing mechanics invisible to the human eye. The acquisition anchored a platform that now layers objective cognitive tests with AI-generated clinical guidance and patient action plans, addressing a care pathway where neurologist demand is projected to outstrip supply by 19% in 2025. The firm deploys capital through two primary channels: provider-facing assessment tools for health systems and a parallel workflow for pharmaceutical trial administrators. Confirmed collaborations include the Davos Alzheimer’s Collaborative, Indiana University School of Medicine, Health Innovation Manchester, and UMass Chan Medical School. Early pilots target primary-care screening, where pathology can exist 15–20 years before overt symptoms — a window the platform’s digital phenotyping aims to capture. Geographic delivery spans US-based health networks and a growing European presence through a Dublin operational hub. Linus has announced 115 professionals across its Boston headquarters and Dublin international office. The 2021 capital raise fueled team expansion and platform R&D, with the technology now referenced in over 160 peer-reviewed publications. No adjacent philanthropic vehicle or family-office club membership has been disclosed. The firm’s customer base splits between risk-bearing provider organizations and life-science companies running cognitive-decline studies, a dual-revenue model uncommon among pure-play digital diagnostic startups. Structurally, Linus Health departs from standard digital-health venture capital by embedding a practicing neurologist — Pascual-Leone — as a co-founder and active CMO, rather than relying solely on a scientific advisory board. That clinical-operating integration shapes product development directly, giving the platform a translational-medicine rhythm that contrasts with the software-first posture of many funded cognitive-health entrants. The firm has not publicly indicated succession plans or a governance shift beyond the founding team.
General information
Firm type
Single Family Office
Year founded
2019
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Boston
Corporate office
867 Boylston Street, 5th Floor, Boston, MA 02116, United States
Additional offices
Dublin, Ireland
Principals
David Bates
Chief Executive Officer
Alvaro Pascual-Leone
Chief Medical Officer
John Showalter
Chief Product Officer
Leah Ray
Chief Customer Officer
Curt Thornton
Chief Business Officer
Seamus Small
Chief Financial Officer
Steve Dutcher
Chief Revenue Officer
Sector focus
Frequently asked questions
Who runs product and clinical strategy at Linus Health?
David Bates serves as CEO; Alvaro Pascual-Leone, a Harvard-affiliated neurologist, acts as Chief Medical Officer. The leadership team also includes a Chief Product Officer, John Showalter, and dedicated chiefs for customer, business, finance, and revenue functions. This embeds clinical and commercial decision-making inside a single executive layer, rather than separating research from go-to-market execution.
How does Linus Health’s technology differ from a standard cognitive screening app?
The platform digitizes validated neuropsychological tests — most notably the Clock Drawing Test — using an iPad and stylus that capture drawing kinematics in real time. AI models analyze process data like hesitation, speed, and pressure, not just the final drawing, detecting subtle impairment signals that pen-and-paper administration misses. The underlying tool originated from 10 years of R&D at MIT and Lahey Hospital & Medical Center.
Does Linus Health operate as a traditional family office or a venture-backed operating company?
Linus Health is structured as a venture-backed digital health operating company, not a family office. It was founded with partners from Tamarisc Ventures and raised $55M in disclosed funding in 2021. The firm builds and sells a SaaS and clinical-trial platform, distinguishing it from investment-holding entities.
Which healthcare settings does Linus Health currently serve?
Linus targets healthcare delivery organizations — such as primary-care practices and health systems — and life-science companies running cognitive-focused clinical trials. Its platform supports early detection in routine primary-care visits and streamlines data collection for researchers studying Alzheimer’s and related dementias. The company has named Indiana University School of Medicine, UMass Chan Medical School, and the UK’s Health Innovation Manchester as active collaborators.
What is Linus Health’s connection to the Davos Alzheimer’s Collaborative?
Linus Health participates in the Davos Alzheimer’s Collaborative’s initiative to expand cognitive screening in primary care globally. The project aims to build evidence for population-level early detection protocols, with Linus providing the digital assessment technology. This partnership situates the firm inside one of the highest-profile multi-stakeholder programs addressing Alzheimer’s disease infrastructure.
How is Linus Health’s international presence structured?
The company maintains its US headquarters in Boston and lists an international headquarters in Dublin, Ireland, via the NexusUCD innovation center. The Dublin office supports European sales and operations, with dedicated contact numbers and a local phone line for general and sales inquiries. No further disclosed offices exist.
What evidence supports the clinical validity of Linus Health’s assessments?
According to the firm, its technology has appeared in over 160 peer-reviewed publications. Those studies have demonstrated sensitivity in detecting subtle cognitive impairment and associations with key Alzheimer’s biomarkers. The original digitized Clock Drawing Test underwent more than a decade of validation at MIT and Lahey Hospital before Linus Health acquired the IP in 2020.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: